Screening for major depressive disorder in adults with cerebral glioma: an initial validation of 3 self-report instruments

Alasdair G. Rooney*, Shanne McNamara, Mairi Mackinnon, Mary Fraser, Roy Rampling, Alan Carson, Robin Grant

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

No depression screening tool is validated for use in cases of cerebral glioma. To address this, we studied the operating characteristics of the Hospital Anxiety and Depression Scale (Depression subscale) (HAD-D), the Patient Health Questionnaire-9 (PHQ-9), and the Distress Thermometer (DT) in glioma patients. We conducted a twin-center prospective observational cohort study of major depressive disorder (MDD), according to the Diagnostic and Statistical Manual, 4th edition, in adults with a new diagnosis of cerebral glioma receiving active management or "watchful waiting." At each of 3 interviews over a 6-month period, patients completed the screening questionnaires and received a structured clinical interview to diagnose MDD. Internal consistency, area under the receiver operating characteristics curve (AUC), sensitivity, specificity, positive predictive value, and positive likelihood ratio were calculated. A maximum of 154 patients completed the DT, 133 completed the HAD-D, and 129 completed the PHQ-9. The HAD-D and PHQ-9 showed good internal consistency (alpha >= 0.77 at all timepoints). Median AUCs were 0.931 +/- 0.074 for the. HAD-D and 0.915 +/- 0.055 for the PHQ-9. The optimal threshold was 7+ for the HAD-D, but 8 + had similar operating characteristics. There was no consistently optimal PHQ-9 threshold, but 10+ was optimal in the largest sample. The DT was inferior to the multi-item instruments. Clinicians can screen for depression in well-functioning glioma patients using the HAD-D at the existing recommended lower threshold of 8+, or the PHQ-9 at a threshold of 10+. Due to a modest positive predictive value of either instrument, patients scoring above these thresholds need a clinical assessment to diagnose or exclude depression.

Original languageEnglish
Pages (from-to)122-129
Number of pages8
JournalNeuro-Oncology
Volume15
Issue number1
DOIs
Publication statusPublished - Jan 2013

Keywords

  • PRIMARY BRAIN-TUMORS
  • SCALE
  • SEVERITY
  • depression
  • glioma
  • screening
  • VALIDITY
  • HOSPITAL ANXIETY
  • TOOL
  • PHQ-9
  • CANCER-PATIENTS
  • POPULATION
  • DISTRESS THERMOMETER

Fingerprint

Dive into the research topics of 'Screening for major depressive disorder in adults with cerebral glioma: an initial validation of 3 self-report instruments'. Together they form a unique fingerprint.

Cite this